Physician profile
Patrick James Mastin
NPI 1811251655
$8,193.07
in general payments reported to CMS, 2019-2025
27 companies · $16.16 in 2025
The $16.16 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,108 · 2022: $4,104 · 2023: $1,915 · 2024: $49.57 · 2025: $16.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,435.69 | 2021-2023 | |
| Amgen INC. | $1,190.18 | 2021-2025 | Enbrel, Otezla, Prolia |
| Janssen Biotech, INC. | $678.43 | 2021-2023 | Simponi Aria, Tremfya, Simponi |
| Novartis Pharmaceuticals Corporation | $481.09 | 2022-2024 | |
| Horizon Therapeutics Plc | $472.06 | 2021-2023 | Krystexxa |
| Lilly USA, LLC | $423.26 | 2021-2023 | Taltz |
| Ucb, INC. | $399.91 | 2021-2023 | Cimzia |
| Astrazeneca Pharmaceuticals LP | $390.01 | 2021-2023 | Saphnelo, Evusheld |
| Glaxosmithkline, LLC. | $370.26 | 2021-2023 | Benlysta |
| Pfizer INC. | $361.57 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $314.15 | 2021-2023 | Acthar |
| Genzyme Corporation | $298.82 | 2021-2023 | |
| Aurinia Pharma U.S., INC. | $285.54 | 2021-2024 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $230.43 | 2021-2023 | Orencia |
| Radius Health, INC. | $218.30 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.47 | 2022-2023 | Ofev, Cyltezo |
| Ultragenyx Pharmaceutical INC. | $121.82 | 2022 | |
| Sobi, INC | $93.38 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $74.99 | 2022 | |
| Genentech USA, INC. | $59.43 | 2023 | Actemra |
| Alexion Pharmaceuticals, INC. | $32.52 | 2022 | |
| Janssen Scientific Affairs, LLC | $29.93 | 2022 | |
| Ani Pharmaceuticals, INC. | $27.63 | 2023 | Purified Cortrophin Gel |
| Organon LLC | $26.92 | 2022-2023 | Renflexis |
| Fresenius Kabi USA, LLC | $20.70 | 2023 | Idacio |
| Takeda Pharmaceuticals U.S.A., INC. | $16.58 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mastin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.